CELLINK and Atelerix team up to enable the shipping at room temperature of fragile 3D bioprinted constructs by the world’s bioprinting community

4th December 2020

CELLINK and Atelerix announced today a partnership to bring to market Atelerix’s portfolio of innova­tive hydrogel biological encapsulation products, which preserve fragile biological samples for shipping at room temperature. Conven­tional shipping methods often involve storing cells and tissues in liquid...

Atelerix Awarded a Position in SLAS’s 2021 Innovation AveNEW

19th November 2020

Atelerix Ltd, innovators in the storage and transport of cells at room temperature, has been chosen to participate in SLAS’s prestigious Innovation AveNEW at SLAS’s 2021 Digital International Conference and Exhibition, taking place online on January 25-27, 2021 at slas.org/2021...

Atelerix awarded Innovate UK funding to enable transport and storage of cellular therapies at room temperature

3rd September 2020

Funding will be used to explore scalable methods of human cell preservation, transport, and re-presentation for clinical applications Cambridge and Newcastle, UK, 03 September 2020: Atelerix Ltd (Atelerix), pioneers in the storage and transport of cells at room temperature, has...

Atelerix Strengthens Its Leadership Team

25th June 2020

Atelerix Strengthens Its Leadership Team Steve Docksey Joining as Executive Chair and Ed Wagena as Chief Operating Officer June 25th 2020 — Cambridge and Newcastle, UK – Atelerix, pioneers in the storage and transport of cells at room temperature, announced...

Atelerix expands availability in Asia

16th June 2020

We are delighted to announce our partnering with key distributors in Asia: Cosmo Bio, Biogenuix and XP Biomed Atelerix announce the signing of distributor agreements with three established and renowned distributors in Asia, and who are now responsible for serving...

Atelerix awarded US patent

9th June 2020

Atelerix awarded the US patent to transport cells in hydrogels Today Atelerix received an Issue Notification from the US Patent and Trade Mark Office, notifying us of the awarding of the patent pertaining to the TRANSPORT OF CELLS IN HYDROGELS. ...

Atelerix granted government funding to help fight COVID-19

26th May 2020

Extending the shelf life of COVID-19 test kits Testing for COVID-19 in the UK, and indeed globally, is a huge task and more testing will be needed to both monitor and control the spread of the disease.  However, a severe...

Atelerix Raises Further Funding of £600,000

14th May 2020

Atelerix raises further funding to develop cell and gene therapy applications.  14th May 2020 — Cambridge and Newcastle, UK – Atelerix, inventors and owners of the innovative cell encapsulation technology, incorporated within the widely used the “Ready” product range, today...

Increasing the accessibility of cell-based therapies

4th May 2020

A case study following the adoption of BeadReady™ for the room temperature shipment of cell therapies in India by Steve Swioklo, Senior Scientist and Co-founder It was the 20th April 2017 when I first visited Hyderabad, to attend a workshop...

Sanj Kumar joins Atelerix as Chief Business Officer

18th November 2019

November 18th 2019 — Cambridge and Newcastle, UK – Atelerix, pioneers in the storage and transport of cells at room temperature, announced today that it has significantly expanded and strengthened the commercialisation of its innovative product range by hiring industry...

Extending the shelf life of fresh cell therapies

7th November 2019

Therapies using live cells offer the possibility of treatments for diseases and conditions that cannot be approached by conventional drugs. Cells are being investigated for their abilities to reverse blindness, re-grow bone and nerves, restore the immune system and treat...

Preserving the Unfreezable

8th October 2019

Cell-based models used in drug discovery and testing are moving away from simple, immortalized cell lines towards systems that more accurately recapitulate an in vivo setting. There is a drive to using primary cells (including patient-specific cells from biopsy samples)...